Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatmentPasi A. Jänne, Melissa L. Johnson, Frédéric Bigot et al.|Molecular Cancer Therapeutics|2023Cited by 60
Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)Jonathan E. Rosenberg, Ahmad Awada, Stéphane Champiat et al.|Cancer Research|2024Cited by 9